BE vs DOV

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full distress risk assessment. Despite explosive revenue growth of 57.1% and strong recent earnings surprises, the company trades at extreme valuations (P/E of 2069, P/B of 52.44) far above sector averages, while profitability remains thin (ROE: 2.93%, net margin: 0.84%). Aggressive insider selling worth $20.85M over the past six months and a bearish technical trend (10/100) further signal caution. Although analysts recommend a 'buy', the stock appears significantly overvalued relative to both defensive (Graham Number: $2.09) and growth-based intrinsic value ($0.49), suggesting elevated downside risk.

Dover Corporation exhibits exceptional fundamental health, evidenced by a strong Piotroski F-Score of 8/9 and a conservative Debt/Equity ratio of 0.44. However, the stock is currently trading at a significant premium, with a current price of $224.78 far exceeding both the Graham Number ($99.42) and the growth-based Intrinsic Value ($119.60). While the company maintains a stellar 25-quarter track record of earnings consistency, bearish insider activity from the CEO and CFO, combined with a weak technical trend, suggests the stock may be overextended. The overall outlook is neutral as high-quality fundamentals are offset by stretched valuation metrics.